Randomized phase III trial in extended stage small cell lung cancer comparing first line platinum in combination with etoposide or topotecan

References

• Caplin ME, Baudin E, Ferolla P, et al. Pulmonary neuroendocrine (carcinoid) tumors: European neuroendocrine tumor society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Ann Oncol. 2015;26(8):1604–1620. doi: 10.1093/annonc/mdv041.
   PubMed Web of Science ®Google Scholar
• Horn L, Mansfield AS, Szczęsna A, et al. First-Line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018; 379(23):2220–2229. doi: 10.1056/NEJMoa1809064.
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394(10212):1929–1939. doi: 10.1016/S0140-6736(19)32222-6.
   PubMed Web of Science ®Google Scholar
• Pujol JL, Carestia L, Daures JP. Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent. Br J Cancer. 2000;83(1):8–15. doi: 10.1054/bjoc.2000.1164.
   PubMed Web of Science ®Google Scholar
• Schiller JH, Kim K, Hutson P, et al. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern cooperative oncology group trial. J Clin Oncol. 1996;14(8):2345–2352. doi: 10.1200/JCO.1996.14.8.2345.
   PubMed Web of Science ®Google Scholar
• von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol. 1999;17(2):658–667. doi: 10.1200/JCO.1999.17.2.658.
   PubMed Web of Science ®Google Scholar
• Rowinsky EK, Kaufmann SH, Baker SD, et al. Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence. J Clin Oncol. 1996;14(12):3074–3084. doi: 10.1200/JCO.1996.14.12.3074.
   PubMed Web of Science ®Google Scholar
• Sorensen M, Jensen PB, Herrstedt J, et al. A dose escalating study of topotecan preceding cisplatin in previously untreated patients with small-cell lung cancer. Ann Oncol. 2000;11(7):829–835. doi: 10.1023/a:1008393512479.
   PubMed Web of Science ®Google Scholar
• Miller AA, Lilenbaum RC, Lynch TJ, et al. Treatment-related fatal sepsis from topotecan/cisplatin and topotecan/paclitaxel. J Clin Oncol. 1996;14(6):1964–1965. doi: 10.1200/JCO.1996.14.6.1964.
   PubMed Web of Science ®Google Scholar
• Seifart U, Jensen K, Ukena J, et al. Randomized phase II study comparing topotecan/cisplatin administration for 5 days versus 3 days in the treatment of extensive stage small cell lung cancer (SCLC). Lung Cancer. 2005;48(3):415–422. doi: 10.1016/j.lungcan.2004.12.003.
   PubMed Web of Science ®Google Scholar
• Sorensen M, Lassen U, Jensen PB, et al. Phase II study of a 3-day schedule with topotecan and cisplatin in patients with previously untreated small cell lung cancer and extensive disease. J Thorac Oncol. 2008;3(8):902–906. doi: 10.1097/JTO.0b013e31817e0f58.
   PubMed Web of Science ®Google Scholar
• Mau-Soerensen M, Hansen O, Holm B, et al. Randomized phase III trial in extensive-disease small cell lung cancer comparing first-line etoposide to topotecan in combination with platinum. J Clin Oncol. 2014;32(15_suppl):7519–7519. doi: 10.1200/jco.2014.32.15_suppl.7519.
   Google Scholar
• Eckardt JR, von Pawel J, Papai Z, et al. Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer. J Clin Oncol. 2006;24(13):2044–2051. doi: 10.1200/JCO.2005.03.3332.
   PubMed Web of Science ®Google Scholar
• Fink TH, Huber RM, Heigener DF, et al. Topotecan/cisplatin compared with cisplatin/etoposide as first-line treatment for patients with extensive disease small-cell lung cancer: final results of a randomized phase III trial. J Thorac Oncol. 2012;7(9):1432–1439. doi: 10.1097/JTO.0b013e318260de75.
   PubMed Web of Science ®Google Scholar
• Lima JP, dos Santos LV, Sasse EC, et al. Camptothecins compared with etoposide in combination with platinum analog in extensive stage small cell lung cancer: systematic review with meta-analysis. J Thorac Oncol. 2010;5(12):1986–1993. doi: 10.1097/JTO.0b013e3181f2451c.
   PubMed Web of Science ®Google Scholar
• Rossi A, Di Maio M, Chiodini P, et al. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol. 2012;30(14):1692–1698. doi: 10.1200/JCO.2011.40.4905.
   PubMed Web of Science ®Google Scholar